In ALCL, CHOP or CHOP plus etoposide remains the first-line therapy [33] and recent clinical trials with anti-CD30 antibody (brentuximab vedotin) have shown substantial activity in the relapsed or refractory disease [34] and front-line treatment [35]. Here, TNFRSF8 is linked to anaplastic large cell lymphoma.